Opus SK Pharmaceuticals

Opus SK Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for central nervous system (CNS) disorders. Established as a joint venture between SK Biopharmaceuticals and Opus Capital, the company is dedicated to advancing a pipeline of small molecule candidates originally discovered by SK Biopharmaceuticals. Its lead programs include SKL24741 for the treatment of epilepsy and SKL13865 for attention deficit hyperactivity disorder (ADHD). Opus SK leverages the drug discovery expertise of SK Group and the strategic investment capabilities of Opus Capital to accelerate clinical progress in the United States. The company aims to address significant unmet needs in neurology and psychiatry through targeted clinical development.